<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Surgery and Cancer</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8E7BDEF1-2830-4C79-8DB5-17E1CD7893C9"><gtr:id>8E7BDEF1-2830-4C79-8DB5-17E1CD7893C9</gtr:id><gtr:firstName>Rohini</gtr:firstName><gtr:surname>Sharma</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/11E636BD-18A8-4C6B-BDB7-D5927ECD0DAE"><gtr:id>11E636BD-18A8-4C6B-BDB7-D5927ECD0DAE</gtr:id><gtr:firstName>Andrea</gtr:firstName><gtr:surname>Frilling</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8524F630-A91D-4A6B-ABEE-87DD63B3194E"><gtr:id>8524F630-A91D-4A6B-ABEE-87DD63B3194E</gtr:id><gtr:firstName>Eric</gtr:firstName><gtr:surname>Aboagye</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/684367A0-B62C-4635-80AE-C558291ACC36"><gtr:id>684367A0-B62C-4635-80AE-C558291ACC36</gtr:id><gtr:firstName>Adil</gtr:firstName><gtr:surname>AL-Nahhas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ007986%2F1"><gtr:id>8E318FC7-46EA-487E-8638-22DD9C6275BE</gtr:id><gtr:title>MICA: DCS - Evaluation of [18F]fluoroethyl triazole labelled [Tyr3]Octreotate analogues for the imaging of neuroendocrine tumours</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J007986/1</gtr:grantReference><gtr:abstractText>The incidence and prevalence of gastroenteropancreatic neuroendocrine tumours (NETs) has been increasing over the past three decades. Due to the high density of somatostatin receptors (SSTR), mainly SSTR2, on the cell surface of these tumours, imaging of tumours is possible. Existing technologies have poor sensitivity and so new methods are being explored. One potential area is the use of 18F-labelled tracers for Positron Emission Tomography (PET) scanning which are much more sensitive and specific to the tumours of interest than exisiting tracers and also have a reduced scanning time. Previous work by this group, under a Developmental Pathway Funding Scheme (DPFS) award, designed five structurally-related [18F]-fluoroethyltriazole-[Tyr3]octreotate analogues. Based on the findings of this work, one candidate compound ( [18F]-FET-betaAG-TOCA) was chosen as the lead compound to take forward into clinical development. We propose to develop [18F]-FET-betaAG-TOCA clinically via a 2 stage trial design. The initial study will assess the pharmacokinetics (PK), biodistribution and safety of the novel tracer employing 'whole body dynamic PET scanning'; of particular interest will be the optimal time for imaging. Using this information we will construct an appropriate protocol for 'whole body static PET scanning' in the subsequent study. We will then compare the diagnostic efficacy of [18F]-FET-betaAG-TOCA PET/CT to [68Ga]-DOTATATE PET/CT (a method currently used for NETs) in patients with a histological diagnosis of NET. These clinical studies will be used as the basis for future larger clinical trials and a Department of Health application to establish this tracer as the new clinical standard based on equivalent sensitivity and specificity but improved kinetics and handling, as well as ease of GMP manufacturing than the existing [68Ga]-DOTATATE PET/CT.</gtr:abstractText><gtr:technicalSummary>The incidence and prevalence of gastroenteropancreatic neuroendocrine tumours (NETs) has been increasing over the past three decades. Due to the high density of somatostatin receptors (SSTR), mainly SSTR2, on the cell surface of these tumours, [111In]-DTPA-octreotide scintigraphy (SRS) has become an important part of clinical management. More recently, however, [68Ga] labelled octreotate analogues are being increasingly used because of their improved sensitivity and specificity (Gabriel et al., 2007). Fluorine-18 radiolabelled analogues with suitable PK would permit positron emission tomography (PET) with more rapid clinical protocols. Previous work by this group, under a Developmental Pathway Funding Scheme (DPFS) award, designed five structurally-related [18F]-fluoroethyltriazole-[Tyr3]octreotate analogues. Based on high binding affinity and low tumour-to-background noise ratio, within this series and also compared to other related F-18 and Ga-68 SSTR imaging agents, we selected [18F]-FET-betaAG-TOCA as the lead compound to take forward into clinical development. We propose to develop [18F]-FET-betaAG-TOCA clinically via a 2 stage trial design. The initial study will assess the pharmacokinetics (PK), biodistribution and safety of the novel tracer employing 'whole body dynamic PET scanning'; of particular interest will be the optimal time for imaging. Using this information we will construct an appropriate protocol for 'whole body static PET scanning' in the subsequent study. We will then compare the diagnostic efficacy of [18F]-FET-betaAG-TOCA PET/CT to [68Ga]-DOTATATE PET/CT in patients with a histological diagnosis of NET. These clinical studies will be used as the basis for future larger clinical trials and a Department of Health application to establish this tracer as the new clinical standard based on equivalent sensitivity and specificity but improved kinetics and handling, as well as ease of GMP manufacturing than the existing [68Ga]-DOTATATE PET/CT.</gtr:technicalSummary><gtr:potentialImpactText>Nuclear medicine physicians, oncologists, endocrinologists and other specialty areas involved in the management of NETs will benefit from a more readily available, accurate diagnostic and staging technique. This will assist with decision making regarding surgery, radiolabelled somatostatin therapy or other systemic agents. Ultimately, more accurate staging will benefit patients. Over the past six months, over sixty patients have been referred to the NET team at the Hammersmith Hospital alone making this tumour a significant problem that requires accurate diagnostic imaging.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-01-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-01-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>781332</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>768583</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J007986/1</gtr:fundingRef><gtr:id>8080718B-B168-4ED6-867D-EA4CA419D54D</gtr:id><gtr:outcomeId>nApSGuSF7fX0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The DPFS grant allowed development of the new imaging compound and pre-clinical assessment to be completed. We have now applied for a DCS grant to allow clinical testing.</gtr:description><gtr:id>7BF411CD-44B9-45A6-94F9-7AB3B62010B2</gtr:id><gtr:impact>Analogues developed resulted in a patent filing. First in Man study due to start end of 2012.</gtr:impact><gtr:outcomeId>Z2Hqz2UgqT3</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogues</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F80D74E6-636B-4ABF-9C6B-0228AB033E23</gtr:id><gtr:title>Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b13ec6403af93922931af218b9cbfdd9"><gtr:id>b13ec6403af93922931af218b9cbfdd9</gtr:id><gtr:otherNames>Mapelli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0143-3636</gtr:issn><gtr:outcomeId>5412fe0baceef0.43131998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37D9818C-98FF-47FE-95DC-2C0A00CCEEE0</gtr:id><gtr:title>Radiopharmaceuticals as probes to characterize tumour tissue.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b13f95cf7a3c55dd20bb63682e25ff9"><gtr:id>0b13f95cf7a3c55dd20bb63682e25ff9</gtr:id><gtr:otherNames>Alam IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>5656f343b9dba1.74422915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4A61DA9-6723-4CEF-B9C1-DAB305D003A4</gtr:id><gtr:title>The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ccd200c9cb196e2fcf98b035d6a71e"><gtr:id>91ccd200c9cb196e2fcf98b035d6a71e</gtr:id><gtr:otherNames>Heinzmann K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>588b2239924e62.85750448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>314E3851-1743-42BC-B39B-2269EC688EC3</gtr:id><gtr:title>Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b13f95cf7a3c55dd20bb63682e25ff9"><gtr:id>0b13f95cf7a3c55dd20bb63682e25ff9</gtr:id><gtr:otherNames>Alam IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>565708976f9645.72397478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F35503D-5353-471F-AF25-2D22C85D44F6</gtr:id><gtr:title>Evaluation ofF-fluorothymidine positron emission tomography ([F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f01aee55e92ee99444433dc058e18197"><gtr:id>f01aee55e92ee99444433dc058e18197</gtr:id><gtr:otherNames>Sharma R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>583594ecae0394.61925449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9F41724-876A-4065-BA12-5EFA9F154FA8</gtr:id><gtr:title>A bioorthogonal (68)Ga-labelling strategy for rapid in vivo imaging.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ae448b0d55f4d694c4a1a62b22106c0"><gtr:id>0ae448b0d55f4d694c4a1a62b22106c0</gtr:id><gtr:otherNames>Evans HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5412fe0da7e550.09839910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0B32D6B-E1B5-4889-B812-020D0CEB8F2F</gtr:id><gtr:title>A novel radiotracer to image glycogen metabolism in tumors by positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6747859800260f7998989a4d593d5fb7"><gtr:id>6747859800260f7998989a4d593d5fb7</gtr:id><gtr:otherNames>Witney TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5412fe0b4440a9.02911451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47193ECC-3B88-41F6-AD10-AFF7FC3C7075</gtr:id><gtr:title>Abstract P5-01-02: Evaluation of apoptosis in breast cancer using the novel PET probe [
 
 F]ICMT-11 in patients treated with neoadjuvant FEC chemotherapy: Initial assessment of optimum imaging time and relation to caspase-3 immunostaining</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c55c8c7e392843664451fb8640557c27"><gtr:id>c55c8c7e392843664451fb8640557c27</gtr:id><gtr:otherNames>Merchant S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5675f17f9526a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1E2BB0A-4D1A-4853-ACF7-7C1B0CF84F5A</gtr:id><gtr:title>The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e79ef5a088d4a1eb36ea8524ee45b1"><gtr:id>b8e79ef5a088d4a1eb36ea8524ee45b1</gtr:id><gtr:otherNames>Trousil S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>57e286bb6f0871.32903512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C4B8EB4-A09E-4EDC-87E6-79DCE938F68B</gtr:id><gtr:title>Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78f0d2c983d64542eca4aba75d3c085"><gtr:id>c78f0d2c983d64542eca4aba75d3c085</gtr:id><gtr:otherNames>Challapalli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>56570896c86523.54388868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C3FBE2F-6DF7-495B-B45B-51D7AC4FF3D8</gtr:id><gtr:title>Imaging biomarker roadmap for cancer studies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>583594ec7d6590.86664788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BBDD053-D800-4F7D-985B-1B3944A0938D</gtr:id><gtr:title>Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e60bc1b7a8608e7140151f94a3962748"><gtr:id>e60bc1b7a8608e7140151f94a3962748</gtr:id><gtr:otherNames>Slade RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>57e24fc90a5959.76015416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D675C5A-04AD-46FA-BFC9-1886338CD095</gtr:id><gtr:title>Mn-salen catalysed benzylic C-H activation for the synthesis of aryl [(18)F]CF3-containing PET probes.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260c018c7e34a0fea0030347894c4c2d"><gtr:id>260c018c7e34a0fea0030347894c4c2d</gtr:id><gtr:otherNames>Carroll L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5656f3440ee7d1.84941307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F842EE2-423B-42D4-B7CC-5D07840CD4C6</gtr:id><gtr:title>Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef57da05671d01a0569e27329ec78e96"><gtr:id>ef57da05671d01a0569e27329ec78e96</gtr:id><gtr:otherNames>Kenny LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56570896eda305.71749333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA3B8E28-75F2-45C6-8339-78105DB4430E</gtr:id><gtr:title>CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14884f7d0f24eafea4348dc8d90f14a5"><gtr:id>14884f7d0f24eafea4348dc8d90f14a5</gtr:id><gtr:otherNames>Gallo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>5412fe0df32ef9.66458238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D531AF3-88A3-4C71-B414-3AC808A9D91D</gtr:id><gtr:title>Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.</gtr:title><gtr:parentPublicationTitle>Frontiers in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78f0d2c983d64542eca4aba75d3c085"><gtr:id>c78f0d2c983d64542eca4aba75d3c085</gtr:id><gtr:otherNames>Challapalli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2234-943X</gtr:issn><gtr:outcomeId>5836b6b7ad2988.09394475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A3BABCF-6044-481D-B033-375E87D963A6</gtr:id><gtr:title>The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17fabfb19208baac057b6f39cfa62200"><gtr:id>17fabfb19208baac057b6f39cfa62200</gtr:id><gtr:otherNames>Hopkins TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>56a8e219a78690.17891095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7D0C759-060C-429F-9368-C0C35DFA258F</gtr:id><gtr:title>Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b13ec6403af93922931af218b9cbfdd9"><gtr:id>b13ec6403af93922931af218b9cbfdd9</gtr:id><gtr:otherNames>Mapelli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>56aa258ea975f2.11246119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5903D7E4-664E-4EFF-B36C-7BBEA99E7919</gtr:id><gtr:title>Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25501ad3972aae03ba145b3fc728ff6f"><gtr:id>25501ad3972aae03ba145b3fc728ff6f</gtr:id><gtr:otherNames>Schug ZT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>56aa258ed57899.00890587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8E6CC88-76B6-4F54-82D3-80FA67D26541</gtr:id><gtr:title>The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f851acbe51a488676f3cf278e2b1edb"><gtr:id>8f851acbe51a488676f3cf278e2b1edb</gtr:id><gtr:otherNames>AbuAli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5412fe0c211f51.27533846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6966ED17-E81C-4E5E-A38E-4AC9A64512ED</gtr:id><gtr:title>Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments.</gtr:title><gtr:parentPublicationTitle>Cancer &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40921e61f7b71eb633519b3ff4ba3425"><gtr:id>40921e61f7b71eb633519b3ff4ba3425</gtr:id><gtr:otherNames>Peck B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2049-3002</gtr:issn><gtr:outcomeId>588b22399339b5.13548726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F4AFAD-B94F-4FE1-A5CB-DB6CAF0BA59E</gtr:id><gtr:title>Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e79ef5a088d4a1eb36ea8524ee45b1"><gtr:id>b8e79ef5a088d4a1eb36ea8524ee45b1</gtr:id><gtr:otherNames>Trousil S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5460b04c795e59.15238254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE2D92D3-B2D8-44EB-B5B2-34A98616345A</gtr:id><gtr:title>Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6747859800260f7998989a4d593d5fb7"><gtr:id>6747859800260f7998989a4d593d5fb7</gtr:id><gtr:otherNames>Witney TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>5412fe0d765fe6.24585788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D436393-8425-45E2-A2BD-7CB85967AA03</gtr:id><gtr:title>3'-Deoxy-3'-&amp;sup1;8F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78f0d2c983d64542eca4aba75d3c085"><gtr:id>c78f0d2c983d64542eca4aba75d3c085</gtr:id><gtr:otherNames>Challapalli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>5656f343ddb6f4.93859372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0436EB2-727E-4E17-950F-69E95D5C1886</gtr:id><gtr:title>Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33553499a1476c772a22378d763efc39"><gtr:id>33553499a1476c772a22378d763efc39</gtr:id><gtr:otherNames>Dubash SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>583594ecd10557.38021838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E61A4E9-FA00-4DA3-A382-E263B1246243</gtr:id><gtr:title>Correction: Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b13f95cf7a3c55dd20bb63682e25ff9"><gtr:id>0b13f95cf7a3c55dd20bb63682e25ff9</gtr:id><gtr:otherNames>Alam IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>585d5c9a796f24.90883473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F75C0180-7F29-4C46-82A4-5EB4AC461B56</gtr:id><gtr:title>Preclinical Applications of 3'-Deoxy-3'-[F]Fluorothymidine in Oncology - A Systematic Review.</gtr:title><gtr:parentPublicationTitle>Theranostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffe5224e6037999c3a82d01373a538e"><gtr:id>2ffe5224e6037999c3a82d01373a538e</gtr:id><gtr:otherNames>Schelhaas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1838-7640</gtr:issn><gtr:outcomeId>588b2239997696.74864657</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J007986/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>